Key facts
- This page summarizes Joseph Truluck's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Mar 2024, 18:07.
Joseph Truluck - 25 Mar 2024 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ADIL
- Reported as of
- 25 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Mar 2024, 18:07:38 UTC
- Prior SEC filing
- 25 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Truluck
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joseph Truluck filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 25 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADIL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.35
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.